Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02685332 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA
A Phase 1 study of Early Stage Breast Cancer, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT02685332: Active Phase 1 study of Early Stage Breast Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT02685332 is a Phase 1 study of Early Stage Breast Cancer that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants, below the 412-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02685332, a Phase 1 study of Early Stage Breast Cancer, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
Radiation, Stereotactic Body Radiation Therapy.
Primary Outcome
maximum tolerated radiation dose
Conditions Studied
Interventions
- RADIATION Stereotactic Radiation
Study Locations (2)
New York
- NYU Winthrop Hospital - Mineola
Texas
- The University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT02685332 still lists
NCT02685332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 412-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Early Stage Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Radiation is the first listed.
NCT02685332 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT02685332 about?
NCT02685332 is a clinical study titled "Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA". Radiation, Stereotactic Body Radiation Therapy.
What is the current status of trial NCT02685332?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-03-31. Estimated completion is 2026-06.
What conditions does trial NCT02685332 study?
This clinical trial studies the following conditions: Early Stage Breast Cancer.
What interventions are being tested in trial NCT02685332?
The interventions under investigation include: Stereotactic Radiation (RADIATION).
Who is sponsoring clinical trial NCT02685332?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02685332 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Stage Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02685332's enrollment target sits among peer trials
30 20th of 21 higher than 1 of 21 other Early Stage Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Stage Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer
COMPLETED · Phase 1
-
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
RECRUITING · Phase 2
-
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RECRUITING
-
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
RECRUITING · NA
-
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
RECRUITING · NA
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI